10x Genomics (TXG) Stock Forecast & Price Target

$14.31 +1.02 (+7.67%)

(As of 11/22/2024 ET)

10x Genomics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
1

Hold
7

Buy
9

Based on 17 Wall Street analysts who have issued ratings for 10x Genomics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 1 has given a sell rating, 7 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for TXG.

Consensus Price Target

$29.19
103.97% Upside

According to the 17 analysts' twelve-month price targets for 10x Genomics, the average price target is $29.19. The highest price target for TXG is $60.00, while the lowest price target for TXG is $14.00. The average price target represents a forecasted upside of 103.97% from the current price of $14.31.

Get the Latest News and Ratings for TXG and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for 10x Genomics and its competitors.

TXG Analyst Ratings Over Time

Type	Current Forecast 11/25/23 to 11/24/24	1 Month Ago 10/26/23 to 10/25/24	3 Months Ago 8/27/23 to 8/26/24	1 Year Ago 11/25/22 to 11/25/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$29.19	$30.60	$31.46	$60.78
Forecasted Upside	103.97% Upside	97.55% Upside	37.99% Upside	40.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

The #1 ETF for monthly income (Ad)

We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.

Click here to get the full story >>

TXG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TXG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

10x Genomics Stock vs. The Competition

Type	10x Genomics	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	103.97% Upside	27,073.48% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent TXG News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/1/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$21.00 ➝ $19.00	+17.87%
10/30/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$35.00 ➝ $23.00	+38.55%
10/30/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Neutral ➝ Neutral	$20.00 ➝ $14.00	-15.92%
10/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$16.00 ➝ $14.00	-15.92%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$25.00 ➝ $20.00	+19.76%
10/10/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00	+92.68%
The #1 ETF for monthly income (Ad) We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th. Click here to get the full story >>
10/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$32.00 ➝ $20.00	+28.53%
9/3/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$35.00	+49.89%
8/13/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$50.00 ➝ $46.00	+134.10%
7/22/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$24.00 ➝ $24.00	+43.71%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $25.00	+26.01%
7/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$53.00 ➝ $25.00	+44.34%
7/10/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$55.00 ➝ $25.00	+36.99%
6/27/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
6/25/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$57.00 ➝ $32.00	+9.29%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$52.00 ➝ $57.00	+23.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:45 PM ET.

TXG Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for 10x Genomics is $29.19, with a high forecast of $60.00 and a low forecast of $14.00.
: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There is currently 1 sell rating, 7 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares.
: According to analysts, 10x Genomics's stock has a predicted upside of 103.97% based on their 12-month stock forecasts.
: Over the previous 90 days, 10x Genomics's stock had 1 upgrade by analysts.
: 10x Genomics has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Stephens, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like 10x Genomics less than other "medical" companies. The consensus rating score for 10x Genomics is 2.53 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TXG compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The #1 ETF for monthly income (Ad)

We just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could start collecting it if you act by December 19th.

Click here to get the full story >>

This page (NASDAQ:TXG) was last updated on 11/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Stock Forecast & Price Target